Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic
| City: |
|
Paris |
| State: |
|
Texas |
| Zip Code: |
|
75460 |
| Conditions: |
|
Metastatic Breast Cancer |
| Purpose: |
|
The purpose of this study is to find out what effect the combination of letrozole (brand
name: Femara) and dasatinib (brand name: Sprycel) has on metastatic breast cancer compared
to letrozole alone
|
| Study Summary: |
|
|
| Criteria: |
|
Inclusion Criteria:
- Has histologic or cytologic diagnosis of breast cancer; evidence of unresectable
locally recurrent or metastatic disease
- Has measurable or evaluable-only disease
- Is female, ≥18 yrs of age, post menopausal or surgically sterile
- HER2 negative, HR+, ER+ and/or PgR+ breast cancer
- 0-1 prior chemotherapy regimen for metastatic disease.
- Prior adjuvant or neoadjuvant chemotherapy completed at least 1 month prior
- Prior tamoxifen therapy is allowed
- No AI therapy for >1 year without recurrence
Exclusion Criteria:
- Pregnant or breast feeding
- Prior hormonal therapy for metastatic or locally recurrent disease
- >1 chemotherapy regimen for metastatic disease
- Pleural or pericardial effusion
- Serious cardiac condition
|
| NCT ID: |
|
NCT00696072 |
| Primary Contact: |
|
Study Director
Bristol-Myers Squibb
Bristol-Myers Squibb
For participation information at a USA site use a phone number below. For site information outside the USA please email:
Email: Clinical.Trials@bms.com
|
| Backup Contact: |
|
First line of email MUST contain NCT# & Site#. Only trial sites that are recruiting have contact information at this time.
|
| Location Contact: |
|
Paris, Texas 75460
United States
Site 015
Site Status: Not yet recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
May 18, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|